Matrix Metalloproteinase (MMP) in Heart Failure

Chronic Stable Heart Failure Clinical Trial

Official title:

MMP is Produced in Failing Hearts

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00663494
• Other study ID #: #244
• Status: Completed
• Phase: N/A
• First received: April 18, 2008
• Last updated: July 20, 2011
• Start date: February 2003
• Est. completion date: July 2006

Study information

• Verified date: April 2008
• Source: Tottori University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the production of MMP in failing hearts.

Description:

Myocardial fibrosis is observed in failing hearts and parallel to the progression of chronic heart failure (CHF) and myocardial remodeling. Matrix metalloproteinases (MMPs) are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with CHF. However, MMPs it is still unclear whether MMPs are produced in failing hearts. Thus, the purpose of this study is to evaluate the production of MMP in failing hearts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 2006
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• chronic stable heart failure

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Stable Heart Failure
• Heart Failure

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tottori University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MMPs level of coronary sinus